Brexpiprazole and Ziprasidone: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Centrally acting medicines may increase drowsiness and problems with attention or coordination. Medicines with overlapping CNS adverse effects may increase drowsiness, impaired attention or dizziness. Medicines that affect the QT interval require a review of the combined cardiac risk.
Clinical significance and safety
Brexpiprazole and Ziprasidone: Centrally acting medicines may increase drowsiness and problems with attention or coordination. Medicines with overlapping CNS adverse effects may increase drowsiness, impaired attention or dizziness. Medicines that affect the QT interval require a review of the combined cardiac risk. Drowsiness, dizziness, reduced coordination and falls can be more likely. Driving and other hazardous tasks require particular caution when affected. The class warning does not mean that every combination is contraindicated or that each pair has been tested in a separate clinical trial. The ziprasidone label advises avoiding other established QT-prolonging drugs. The relevant antipsychotic information calls for caution with QT-active partners; this is not a claim that it consistently causes clinically important QT prolongation on its own. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.